CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

Nano Today is a prestigious journal published by ELSEVIER SCI LTD that stands at the forefront of nanoscience and nanotechnology research. With an impact factor that underscores its significance, this journal has achieved remarkable rankings in several key categories as of 2023, including Q1 positions in Bioengineering, Biomedical Engineering, Biotechnology, Materials Science, and Pharmaceutical Science, making it an essential resource for scholars and professionals alike. ISSN 1748-0132 and E-ISSN 1878-044X, the journal serves as a vital platform for disseminating cutting-edge research findings and innovative applications in the field. Although open access options are not available, the journal's rich repository of peer-reviewed articles provides invaluable insights into the latest advancements in nanotechnologies. Based in the Netherlands, Nano Today not only connects a global network of researchers but also propels forward the conversation on the transformative potential of nanomaterials across multiple disciplines. With a commitment to advancing knowledge and fostering innovation, Nano Today is an indispensable tool for academics and practitioners dedicated to pushing the boundaries of scientific exploration.

MOLECULES, published by MDPI, stands as a prominent open-access journal dedicated to the field of chemistry, with an exceptional reputation in various sub-disciplines. Since its inception in 1997, this journal has committed itself to the dissemination of innovative research, spanning topics in Analytical Chemistry, Organic Chemistry, Pharmaceutical Science, and Drug Discovery. With impressive rankings across Scopus categories—including a coveted Q1 designation in both Analytical Chemistry and Pharmaceutical Science—MOLECULES is recognized as a vital resource for researchers, professionals, and students aiming to stay at the forefront of scientific development. The journal’s data reflect its wide-ranging influence, holding high percentiles in multiple chemistry categories, thereby ensuring that its articles reach a significant audience. As an open-access journal, it provides unparalleled access to its content, available freely and globally, which promotes further advancement and collaboration within the scientific community. Its ongoing commitment to high-quality research from 1996 to 2024 reinforces its status as a leader in the academic publishing landscape.

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.

ACS Biomaterials Science & Engineering, published by the American Chemical Society, serves as a premier platform for the latest advancements and research in the fields of biomaterials and biomedical engineering. With an impressive impact factor and a strong reputation reflected in its ranking—Q2 in Biomaterials and Q1 in Biomedical Engineering—the journal attracts a diverse and engaged readership. Since its inception in 2015, it has aimed to foster innovation by publishing high-quality research articles, reviews, and perspectives on the synthesis, characterization, and application of biomaterials. Researchers and professionals benefit from the journal's rigorous peer-review process and its focus on translational science, making it essential for those looking to stay at the forefront of biomaterials research. Located in Washington, DC, USA, the journal plays a pivotal role in connecting academic and industrial sectors, ultimately driving advancements that impact biomedicine and related fields.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.